Saikosaponin A

SSa’s marquee signal and the pharmacological rationale behind chai hu’s traditional “harmonising” reputation. SSa (with its epimer SSd) suppresses NF-κB signalling, lowering iNOS/COX-2 and pro-inflammatory cytokines in macrophage/LPS models ^{1Reference 1Zhu J et al. · 2013Saikosaponin A and its epimer saikosaponin D exhibit anti-inflammatory activity by suppressing activation of the NF-κB signalling pathwayView study →}, and tumour-microenvironment immunomodulation is an active SSa theme ^{3,4Reference 3Chen Z et al. · 2026Saikosaponin A alleviates hepatocellular-carcinoma growth induced by chronic stress via regulating the tumour immune microenvironmentView study →Reference 4Li Y et al. · 2026Emerging role of saikosaponin A in tumour therapy and tumour-microenvironment immunomodulationView study →}.

Gap: in-vitro/rodent only; the clinical anti-inflammatory effect belongs to the whole formula, and the effective concentrations are unlikely to be reached from oral herb intake ^{1Reference 1Zhu J et al. · 2013Saikosaponin A and its epimer saikosaponin D exhibit anti-inflammatory activity by suppressing activation of the NF-κB signalling pathwayView study →}.

The broadest signal after anti-inflammatory, and a clean sibling contrast. SSa suppressed angiogenesis and tumour growth by blocking VEGFR2-mediated signalling ^{2Reference 2Zhao X et al. · 2021Saikosaponin A, a triterpene saponin, suppresses angiogenesis and tumour growth by blocking the VEGFR2-mediated signalling pathwayView study →} — mechanistically opposite to the pro-angiogenic SSc — and induced apoptosis in neuroblastoma cells ^{5Reference 5Wang J et al. · 2021Antitumour effect of saikosaponin A on human neuroblastoma cellsView study →}; in vivo it curbed chronic-stress-driven hepatocellular-carcinoma growth by remodelling the tumour immune microenvironment ^{3,4Reference 3Chen Z et al. · 2026Saikosaponin A alleviates hepatocellular-carcinoma growth induced by chronic stress via regulating the tumour immune microenvironmentView study →Reference 4Li Y et al. · 2026Emerging role of saikosaponin A in tumour therapy and tumour-microenvironment immunomodulationView study →}.

Gap: entirely preclinical (cell lines + xenograft/mouse), at cytotoxic concentrations, with no human oncology data ^{2,3Reference 2Zhao X et al. · 2021Saikosaponin A, a triterpene saponin, suppresses angiogenesis and tumour growth by blocking the VEGFR2-mediated signalling pathwayView study →Reference 3Chen Z et al. · 2026Saikosaponin A alleviates hepatocellular-carcinoma growth induced by chronic stress via regulating the tumour immune microenvironmentView study →}.

A genuine but double-edged signal. SSa improved hepatic antioxidant capacity and protected against CCl₄-induced liver injury in rats ^{6Reference 6Wu SJ et al. · 2008AnimalCurcumin or saikosaponin A improves hepatic antioxidant capacity and protects against CCl₄-induced liver injury in ratsView study →} — yet it is also a SERCA inhibitor implicated in the hepatotoxicity of Bupleurum preparations ^{9Reference 9Ye Q et al. · 2017Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →}.

Gap: one rodent protective model set against a real class hepatotoxicity liability — this is not clean liver protection, and the direction depends on dose ^{6,9Reference 6Wu SJ et al. · 2008AnimalCurcumin or saikosaponin A improves hepatic antioxidant capacity and protects against CCl₄-induced liver injury in ratsView study →Reference 9Ye Q et al. · 2017Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →}.

Fitting the chai-hu “shu gan”/mood context, SSa showed antidepressant-like effects via the TLR4 → NF-κB/BDNF axis with reduced oxidative stress/neuroinflammation ^{7Reference 7Su J et al. · 2025In vitroTLR4 as a therapeutic target: antidepressant mechanism of saikosaponin A in regulating the NF-κB/BDNF axis and mitigating oxidative stress and inflammation in vivo and in vitroView study →}, and promoted hippocampal neurogenesis via Tet1/Dll3/Notch1 signalling in mice ^{8Reference 8Lin J et al. · 2024AnimalSaikosaponin A activates Tet1/Dll3/Notch1 signalling and promotes hippocampal neurogenesis to improve depression-like behaviour in miceView study →}.

Gap: rodent-only, single-molecule, with no human data and the saponin oral-bioavailability caveat applying throughout ^{7,8Reference 7Su J et al. · 2025In vitroTLR4 as a therapeutic target: antidepressant mechanism of saikosaponin A in regulating the NF-κB/BDNF axis and mitigating oxidative stress and inflammation in vivo and in vitroView study →Reference 8Lin J et al. · 2024AnimalSaikosaponin A activates Tet1/Dll3/Notch1 signalling and promotes hippocampal neurogenesis to improve depression-like behaviour in miceView study →}.